
ProMIS Neurosciences Investor Relations Material
Latest events

Q1 2025
12 May, 2025

Q4 2024
31 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ProMIS Neurosciences Inc
Access all reports
ProMIS Neurosciences Inc is a Canada-based biotechnology company focused on the discovery and development of antibody therapeutics for neurodegenerative diseases. The company uses a proprietary computational platform to design monoclonal antibodies that selectively target toxic misfolded proteins implicated in conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. ProMIS conducts preclinical and early-stage clinical development in collaboration with academic and industry partners. The company is headquartered in Toronto, Ontario, and its shares are listed on the TSX.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
PMN
Country
🇺🇸 United States